GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...

What is Ozempic teeth? Here is what you need to know about how the weight loss drug Ozempic may be impacting your health.

The UK’s drug regulator is to study possible serious side effects of glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). Data from ...

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...

Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 ...

GLP-1 therapies primarily use single-use injectable pens, contributing to medical waste challenges. The pharmaceutical ...

Viking Therapeutics initiates VANQUISH phase 3 obesity clinical programme with GLP-1/GIP agonist VK2735: San Diego Thursday, June 26, 2025, 10:00 Hrs [IST] Viking Therapeutics, In ...